Jeanne Calment of France died in 1997 at 122 years and 164 days. Nobody has come close to matching that age since. The figure is not written in any law of physics or encoded in any gene, but it has held steady for nearly three decades.
A team of Russian researchers published a study this month that calculates exactly where the biological ceiling sits if science manages to cure nearly every known cause of aging. Their conclusion: under the most optimistic biological scenario, most humans would still die before their 200th birthday. The figure they arrived at is 156 years. The thing that would kill you, even in that future, is not cancer, heart disease, or dementia. It is random DNA damage in cells that cannot replace themselves.
What the New Research Actually Found
The study, authored by Evgeniy Efimov, Vlad Fedotov, and Leonid Malaev, was published in npj Aging in 2026. The researchers, based at Russia’s Skolkovo Institute of Science and Technology (Skoltech) and the Artificial Intelligence Research Institute (AIRI), asked what would happen if future medicine could eliminate all major causes of aging except somatic mutations.
Somatic mutations are random changes in DNA that occur in the body’s cells throughout life. Unlike germline mutations, they are not inherited, but they accumulate with age and can damage cells, impair their function, and contribute to age-related diseases. Every time a cell divides and copies its genetic material, errors creep in. Environmental exposures add more. Most of these errors are harmless. Some are not.
The researchers developed a multistage mathematical model that allowed them to sequentially remove various aging processes and assess how long a person could live if all reversible aging processes were eliminated except somatic mutations. The reversible processes they stripped away include cellular senescence (the accumulation of aged, non-dividing cells), mitochondrial dysfunction, and telomere shortening. In this thought experiment, all of those are cured. The only process left running is the steady accumulation of DNA copying errors.
Neurons and cardiomyocytes turned out to be the main limiting factors. These cells lack the ability to divide. When all other causes of aging are eliminated, somatic mutations alone reduce the theoretical median lifespan from 1,759 years, for a hypothetical non-aging human organism, to 156 years.
That drop from 1,759 to 156 means that if you could halt every other biological clock simultaneously, random DNA damage in your brain and heart would still kill you in roughly a century and a half.
Why the Brain and Heart Are the Bottleneck
Post-mitotic cells act as critical longevity bottlenecks. Proliferating tissues like the liver maintain functionality for thousands of years through cellular replacement, effectively neutralizing mutation-driven decline. The liver regenerates constantly, diluting accumulated damage through new cell growth. The brain and the heart cannot do the same.
The neurons you were born with are largely the neurons you will die with. Every mutation they accumulate is permanent. Those mutations build up in long-lived cells that cannot readily be replaced.
Depending on the model’s assumptions, the median lifespan ranged from 146 to 194 years. A few exceptional individuals might theoretically live much longer, but no one would live forever. The researchers also noted that in extreme statistical outliers, a person in 100,000 might approach 470 years, but those figures sit so far outside the modeled probability distribution that they function more as a mathematical curiosity than a genuine prediction.
Efimov stated that the study is not intended to suggest people will actually live for 156 or 190 years. The model is a thought experiment, a tool for measuring the relative contribution of one biological process to aging.
The Prior Consensus: A Wall at 120
Before this study, the dominant figure in aging science was 120 to 122 years, essentially the age Jeanne Calment reached. Many researchers had long believed the human lifespan has a natural upper limit of about 122 years under current biological conditions.
The Skoltech study reframes that consensus. The 122-year figure describes what happens when all the usual biological aging processes are running at full capacity. The new 156-year figure describes what happens when most of those processes are corrected. The gap between the two, about 34 years, represents the theoretical gains that future medicine might eventually unlock, even without solving the mutation problem.
A Separate Question: Have We Already Hit a Wall?
While the Skoltech model asks what biology ultimately allows, a different body of research asks whether humans are approaching a ceiling right now, with today’s medicine.
A paper published in Nature Aging in October 2024 concluded that we are unlikely to see significant leaps in human life expectancy this century. The study looked at advances in human life expectancy between 1990 and 2019 in countries where people typically live the longest. Average life expectancy went up, but maximum lifespan did not change. The pace of increase in average life expectancy has slowed, and medical and public health advances over that period have not slowed human aging or done anything to radically prolong lifespan.
William Mair, professor of molecular metabolism at Harvard T.H. Chan School of Public Health, summarized the distinction clearly: modern medicine has been extraordinarily effective at keeping people alive longer by treating disease, but it has not actually slowed the underlying biological process of aging itself. Life expectancy and maximum lifespan are not the same number, and they respond to different interventions.
In the United States, life expectancy at birth increased from about 47 years at the beginning of the 20th century to around 77 years by the century’s end, according to CDC data. That roughly 64% increase translates to an average yearly gain of about 0.30 years. The gains came from defeating infectious disease, improving sanitation, and reducing childhood mortality. Aging biology itself was not the target.
An analysis of three decades of data suggests that without significant scientific breakthroughs, the maximum predicted life expectancy plateaus around 87 years: 84 for men and 90 for women. That plateau is not a law of nature. It is the limit of what conventional medicine, doing what it currently does, can achieve.
The Processes Science Is Trying to Fix
The Skoltech model is built around a framework that has become central to longevity biology: the hallmarks of aging. These are the molecular and cellular processes that researchers have identified as primary drivers of biological decline. The study isolates one of them from the rest with deliberate precision.
Researchers from the Skolkovo Institute modeled what would happen if most established processes, including cellular senescence, mitochondrial dysfunction, and telomere shortening, were substantially mitigated. The goal was not to suggest these cures are imminent, but to create a controlled experimental condition in which the contribution of somatic mutations could be measured independently.
The study found that different organs respond very differently to DNA mutation damage. The brain and the heart are particularly vulnerable because some of their critical cells are irreplaceable. They rarely divide or get replaced after birth. The liver, in contrast, constantly replaces worn-out cells. Aging is not just a systemic process but a spatially uneven one, where the slowest-regenerating tissues set the pace for the whole organism.
Newsweek reported that Assistant Professor Jordan Weiss, who studies health span and population-level aging at NYU Grossman School of Medicine, said the model’s tissue-specific insight mirrors real-world patterns: the conditions that cost people their independent, healthy years fall heavily on precisely the tissues that cannot regenerate.
What It Would Take to Go Further
The Skolkovo scientists set out to understand whether there is a hard limit on how long humans could live if every major cause of aging was eliminated except for somatic mutations. No existing treatment can reverse the damage they cause within human cells.
The research community has proposed several theoretical routes to controlling somatic mutation accumulation. Gene editing technologies could, in principle, repair damaged DNA in non-dividing cells. Stem cell therapies might allow the selective replacement of mutated neurons with healthy ones. More speculative proposals involve slowing the rate of mutation accumulation by enhancing DNA repair enzymes.
ScienceAlert noted that lead researcher Dmitrii Kriukov described the ceiling as a way of highlighting that somatic mutations may become critical when combined with other aging drivers. The 1,759-year baseline in the model, the theoretical lifespan of a human who ages by no process whatsoever, is not a goal. It is a mathematical artifact that reveals how much biological work aging actually does. Add mutations back in to that baseline and the lifespan drops to 156.
The collection of processes that other researchers are actively pursuing includes senescent cells that accumulate and inflame surrounding tissue, mitochondria that lose efficiency over decades, and telomeres that shorten with each cell division until replication stops. Each of these has its own research literature, its own therapeutic candidates, and its own projected timelines for clinical intervention. The Skoltech study’s message to that entire field is both encouraging and sobering: cure all of it, and you have roughly doubled human longevity. You have not ended it.
The Oldest People Alive Today and What They Tell Us
The world’s oldest living person, as of 2026, is Ethel Caterham of the United Kingdom, who is 116 years old. Long-lived individuals such as centenarians often have siblings with similar favorable genetics. But longevity, even in exceptional cases, runs against a wall somewhere around 120 years that modern medicine has not moved in any documented case.
The question of whether that wall is biological or merely statistical is one the Skoltech study engages directly. Their model suggests it is both. Even in a population free of disease, free of age-related cellular dysfunction, and free of every other compounding factor, somatic mutations alone would thin the ranks significantly before anyone approached 200.
Key Takeaways
The Skoltech team’s modeling framework estimates that if all aging processes were eliminated except somatic mutations, post-mitotic cells such as neurons and cardiomyocytes act as critical longevity bottlenecks, reducing median lifespan from a theoretical non-aging baseline of 1,759 years to 156 years. That figure, ranging across model assumptions from 146 to 194 years, represents the most rigorous quantitative estimate yet produced of the maximum human lifespan under biologically optimistic conditions.
Separately, research covering 1990 to 2019 in the world’s longest-lived populations found that while average life expectancy rose, maximum lifespan did not change, and the pace of gains has since slowed. The medicine of today has pushed average life expectancy close to what it can achieve without directly targeting the biology of aging. To move the needle further will require a different category of intervention entirely.
The path between a current median US lifespan of 79 years and a theoretical biological ceiling of 156 runs through the cell itself, through the DNA errors that pile up in neurons decade after decade, through the heart muscle cells that absorb damage they can never offload. Whether science finds a way to address those processes in a living human brain and a beating heart is genuinely unknown.
What to Do With All of This
Somatic mutations in non-renewing tissue are the hardest problem in geroscience. They lack a single druggable pathway, cannot be flushed out, and cannot be diluted through cell turnover in a brain or a heart. Companies targeting senescent cells, telomere dynamics, and mitochondrial repair are addressing processes that the Skoltech model treated as, in principle, solvable. Non-dividing cells accumulating permanent DNA errors are a different category of problem entirely.
For the individual reading this in 2026, none of those interventions are available at a pharmacy or even in a clinical trial. Lifestyle factors such as exercise, diet, sleep, and not smoking address the reversible processes that the Skoltech model assumed away. They are worth doing not because they will push anyone to 156, but because they address the biological processes that, in the real world, will kill most people long before somatic mutations become the binding constraint. The mutation ceiling only becomes relevant once everything else has been managed. For the overwhelming majority of people alive today, everything else has not been managed.
Rather than predicting how long humans might live, the researchers say their framework offers a new way to measure the contribution of different biological processes to aging. Science has spent decades arguing about whether a hard lifespan ceiling exists at all. This study changes the terms of that argument. The ceiling is real, it is quantifiable, and it moves depending on which biological problems you solve. The goal of longevity research is no longer just to find a number. It is to understand, precisely, what is holding the number where it is.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.